DRDiana Riebold

Diana Riebold

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Diana Riebold has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Axenic Long-Term Cultivation of Pneumocystis jirovecii

    by Diana Riebold, Marie Mahnkopf, Kristina Wicht, Cristina Zubiria-Barrera, Jan Heise, Marcus Frank, Daniel Misch, Torsten Bauer, Hartmut Stocker, Hortense Slevogt

    Pneumocystis jirovecii, a fungus causing severe Pneumocystis pneumonia (PCP) in humans, has long been described as non-culturable. Only isolated short-term experiments with P. jirovecii and a small number of experiments involving animal-derived Pneumocystis species have been published to date. However, P. jirovecii culture conditions may differ significantly from those of animal-derived Pneumocystis, as there are major genotypic and phenotypic differences between them. Establishing a well-performing P. jirovecii cultivation is crucial to understanding PCP and its pathophysiological processes. The aim of this study, therefore, was to develop an axenic culture for Pneumocystis jirovecii. To identify promising approaches for cultivation, a literature survey encompassing animal-derived Pneumocystis cultures was carried out. The variables identified, such as incubation time, pH value, vitamins, amino acids, and other components, were trialed and adjusted to find the optimum conditions for P. jirovecii culture. This allowed us to develop a medium that produced a 42.6-fold increase in P. jirovecii qPCR copy numbers after a 48-day culture. Growth was confirmed microscopically by the increasing number and size of actively growing Pneumocystis clusters in the final medium, DMEM-O3. P. jirovecii doubling time was 8.9 days (range 6.9 to 13.6 days). In conclusion, we successfully cultivated P. jirovecii under optimized cell-free conditions in a 70-day long-term culture for the first time. However, further optimization of the culture conditions for this slow grower is indispensable.


  • First molecular detection of Pneumocystis spp. in red foxes (Vulpes vulpes linnaeus, 1758) and raccoon dogs (Nyctereutes procyonoides gray, 1834)

    by Diana Riebold, Jacob Lubig, Peter Wolf, Carola Wolf, Kati Russow, Micha Loebermann, Hortense Slevogt, Elmar Mohr, Frerk Feldhusen, Emil Christian Reisinger


  • Occurrence of Gastrointestinal Parasites in Small Mammals from Germany

    by Diana Riebold, Kati Russow, Mathias Schlegel, Theres Wollny, Jörg Thiel, Jona Freise, Ommo Hüppop, Jana Anja Eccard, Anita Plenge-Bönig, Micha Loebermann, et al.

    An increase in zoonotic infections in humans in recent years has led to a high level of public interest. However, the extent of infestation of free-living small mammals with pathogens and especially parasites is not well understood. This pilot study was carried out within the framework of the “Rodent-borne pathogens” network to identify zoonotic parasites in small mammals in Germany. From 2008 to 2009, 111 small mammals of 8 rodent and 5 insectivore species were collected. Feces and intestine samples from every mammal were examined microscopically for the presence of intestinal parasites by using Telemann concentration for worm eggs, Kinyoun staining for coccidia, and Heidenhain staining for other protozoa. Adult helminths were additionally stained with carmine acid for species determination. Eleven different helminth species, five coccidians, and three other protozoa species were detected. Simultaneous infection of one host by different helminths was common. Hymenolepis spp. (20.7%) were the most common zoonotic helminths in the investigated hosts. Coccidia, including Eimeria spp. (30.6%), Cryptosporidium spp. (17.1%), and Sarcocystis spp. (17.1%), were present in 40.5% of the feces samples of small mammals. Protozoa, such as Giardia spp. and amoebae, were rarely detected, most likely because of the repeated freeze-thawing of the samples during preparation. The zoonotic pathogens detected in this pilot study may be potentially transmitted to humans by drinking water, smear infection, and airborne transmission.


  • Open Access

    IL-37 Causes Excessive Inflammation and Tissue Damage in Murine Pneumococcal Pneumonia

    by Anja E. Schauer, Tilman E. Klassert, Carolin von Lachner, Diana Riebold, Anne Schneeweiß, Magdalena Stock, Mario M. Müller, Sven Hammerschmidt, Philip Bufler, Ulrike Seifert, et al.

    Streptococcus pneumoniae infections can lead to severe complications with excessive immune activation and tissue damage. Interleukin-37 (IL-37) has gained importance as a suppressor of innate and acquired immunity, and its effects have been therapeutic as they prevent tissue damage in autoimmune and inflammatory diseases. By using RAW macrophages, stably transfected with human IL-37, we showed a 70% decrease in the cytokine levels of IL-6, TNF-α, and IL-1β, and a 2.2-fold reduction of the intracellular killing capacity of internalized pneumococci in response to pneumococcal infection. In a murine model of infection with S. pneumoniae, using mice transgenic for human IL-37b (IL-37tg), we observed an initial decrease in cytokine expression of IL-6, TNF-α, and IL-1β in the lungs, followed by a late-phase enhancement of pneumococcal burden and subsequent increase of proinflammatory cytokine levels. Additionally, a marked increase in recruitment of alveolar macrophages and neutrophils was noted, while TRAIL mRNA was reduced 3-fold in lungs of IL-37tg mice, resulting in necrotizing pneumonia with augmented death of infiltrating neutrophils, enhanced bacteremic spread, and increased mortality. In conclusion, we have identified that IL-37 modulates several core components of a successful inflammatory response to pneumococcal pneumonia, which lead to increased inflammation, tissue damage, and mortality.


  • Pneumocystis pneumonia (PCP) and Pneumocystis jirovecii carriage in renal transplantation patients: a single-centre experience

    by Matthias Maruschke, Diana Riebold, Martha Charlotte Holtfreter, Martina Sombetzki, Steffen Mitzner, Micha Loebermann, Emil Christian Reisinger, Oliver W. Hakenberg

    The Pneumocystis pneumonia is an increasing problem in transplanted patients: up to 25 % suffer from Pneumocystis pneumonia, occurring during the first 6 months after transplantation. From 2001 to 2009, we investigated 21 patients with pneumonia after renal transplantation for the presence of Pneumocystis jirovecii. The laboratory diagnosis was established by Grocott and Giemsa staining methods and Pneumocystis-specific mitochondrial transcribed large subunit nested polymerase chain reaction (PCR). The PCR was also used for the differentiation of Pneumocystis pneumonia from Pneumocystis carriage. Of 21 patients, 7 had a Pneumocystis pneumonia, 6 were Pneumocystis carriers and 8 patients were negative. Four out of seven Pneumocystis pneumonia patients and two out of six patients with Pneumocystis carriage had a delayed graft function. An acute cytomegalovirus infection after transplantation was not detectable in the patients with Pneumocystis pneumonia, but in three patients with Pneumocystis carriage. Pneumocystis pneumonia was present in 33.3 % of transplanted patients with suspected pneumonia. An association between acute rejection or co-infections and Pneumocystis pneumonia or carriage in patients after renal transplantation cannot be excluded. In three out of seven Pneumocystis pneumonia patients, an overlapping of hospitalisation times and an onset of Pneumocystis pneumonia 6 months after transplantation was found. Thus, person-to-person transmission seems probable in these cases. Die Pneumocystis Pneumonie stellt in zunehmendem Maße ein Problem bei Patienten nach Transplantationen dar: bis zu 25 % der Patienten erkranken an einer Pneumocystis Pneumonie, die innerhalb der ersten sechs Monate nach Transplantation auftritt. Von 2001 bis 2009 wurde bei 21 Patienten nach Nierentransplantation eine Pneumonie durch Pneumocystis jirovecii vermutet. Die Labordiagnostik erfolgte mittels Grocott- und Giemsa-Färbungen sowie Pneumocystis-spezifischer „mitochondrial transcribed large subunit“ nested PCR. Diese PCR wurde zusätzlich zur Differenzierung zwischen einer Pneumocystis Pneumonie und einer Pneumocystis Besiedelung genutzt. Bei 7/21 Patienten wurde eine Pneumocystis Pneumonie nachgewiesen, 6 waren mit Pneumocystis besiedelt und 8 Patienten waren negativ. 4/7 Pneumocystis Pneumonie Patienten sowie 2/6 Patienten mit Pneumocystis Besiedlung hatten eine verzögerte Transplantat-Funktion. Eine akute Cytomegalie-Virus-Infektion nach Transplantation trat bei keinem der Pneumocystis Pneumonie-Fälle und bei drei Patienten mit Pneumocystis Besiedelung auf. Eine Pneumocystis Pneumonie konnte bei 33,3 % der Patienten nach Nierentransplantation und Verdacht auf Pneumonie nachgewiesen werden. Eine Assoziation zwischen akuter Rejektion oder Koinfektionen und dem Auftreten einer PCP bzw. Besiedelung war nicht auszuschließen. Bei 3/7 Pneumocystis Pneumonie Patienten wurde eine Überschneidung der Hospitalisierungs-Zeiträume mit gleichzeitigem Beginn der Pneumocystis Pneumonie sechs Monate nach Transplantation festgestellt. Eine Übertragung von Person zu Person scheint in diesen Fällen sehr wahrscheinlich.


  • Open Access

    Clinical Trial to Evaluate the Safety and Immunogenicity of a Trivalent Surface Antigen Seasonal Influenza Vaccine Produced in Mammalian Cell Culture and Administered to Young and Elderly Adults with and without A(H1N1) Pre-Vaccination

    by Micha Loebermann, Ulrich Voss, Seetha Meyer, Dietrich Bosse, Carlos Fritzsche, Sebastian Klammt, Silvius Frimmel, Diana Riebold, Emil C. Reisinger

    Vaccination against influenza is an important means of reducing morbidity and mortality in subjects at risk. The prevalent viral strains responsible for seasonal epidemics usually change annually, but the WHO recommendations for the 2011/2012-season in the Northern hemisphere included the same antigens as for the previous season. We conducted a single-center, single-arm study involving 62 younger (18–60 years) and 64 older (>60 years) adults to test the immunogenicity, safety and tolerability of a trivalent surface antigen, inactivated influenza vaccine produced in mammalian cell-culture. The vaccine contained 15 µg hemagglutinin of each of the virus strains recommended for the 2011–2012 Northern hemisphere winter season (A/California/7/09 (H1N1)-; A/Perth/16/09 (H3N2)-; B/Brisbane/60/08-like strain) in a non-adjuvanted preservative-free formulation. Antibody response was measured by hemagglutination inhibition 21 days after immunization. Adverse events and safety were assessed using subject diary cards and telephone interviews. Seroconversion or a 4-fold antibody increase in antibody titers was detectable against A(H1N1) in 68% of both younger and older adults, against A(H3N2) in 53% and 27%, and against the B influenza strain in 35% and 17%. Antibody titers of 40 or more were observed against A(H1N1) in 87% and 90% of younger and older adults, against A(H3N2) in 98% and 98%, and against the B influenza strain in 93% and 90%. Pre-vaccination antibody titers were protective against A(H1N1), A(H3N2) and B in 38%, 58% and 58%, respectively, of younger and in 43%, 88% and 70% of older adults. Among subjects with previous A(H1N1) vaccination only 48% of younger and 47% of older adults had protective A(H1N1) antibodies at inclusion. Adverse reactions were generally mild. The most frequently reported reactions were pain at the injection site, myalgia and fatigue. The vaccine generated protective antibodies against all three viral strains and had an acceptable safety profile in both younger and older adults. ClinicalTrials.gov NCT01422512


  • Pneumocystis jirovecii colonization among renal transplant recipients

    by Carlos Fritzsche, Diana Riebold, Andreas Fuehrer, Andrea Mitzner, Sebastian Klammt, Brigitte Mueller‐Hilke, Emil C Reisinger

    Aim: Renal transplant recipients are at risk of developing Pneumocystis pneumonia (PcP), especially in the first 2 years after transplantation, with a mortality rate of up to 50%. No data are available on pulmonary colonization with Pneumocystis jirovecii in renal transplant recipients. The aim of this study was to determine the prevalence of pulmonary colonization with Pneumocystis jirovecii in renal transplant recipients and to find related risk factors.Methods: We investigated the induced sputa of 70 renal transplant recipients for the presence of Pneumocystis jirovecii using nested polymerase chain reaction.Results: Thirteen of 70 patients (18.6%) were colonized with Pneumocystis jirovecii. There was no significant correlation between colonization and immunosuppressive medication or regimens. However, colonized subjects had undergone transplantation longer ago than non‐colonized subjects. 30.8% of those whose transplantation had taken place more than 8 years previously were colonized, in contrast to 11.4% of those whose transplantation had taken place less than 8 years ago (P = 0.059; odds ratio = 3.467, 95% confidence interval = 0.99–12.09).Conclusion: Most cases of Pneumocystis colonization were detected in those patients where renal transplantion had taken place more than 2 years previously. As most PcP cases occur within the first 2 years of transplantation, colonization does not seem to play a role in the development of acute PcP in this period. Though Pneumocystis pneumonia is likely to be a newly acquired infection in the first 2 years after transplantation, colonized patients remain a potential source of transmission of Pneumocystis jirovecii.


  • Hepatitis B and C: neglected diseases among health care workers in Cameroon

    by C. Fritzsche, F. Becker, C. J. Hemmer, D. Riebold, S. Klammt, F. Hufert, W. Akam, T. N. Kinge, E. C. Reisinger

    Background Healthcare workers (HCW) are at risk of acquiring blood-borne viral infections, particularly hepatitis B (HBV), hepatitis C (HCV), and HIV, especially in high endemic regions such as sub-Saharan Africa. Methods Sera from 237 hospital workers in Southwest Cameroon were tested for anti-hepatitis B core antigen (anti-HBc), hepatitis B surface antigen (HBsAg), anti-hepatitis B surface antigen (anti-HBs), anti-HCV and (on a voluntary basis) for anti-HIV. Information on pre-study testing for HBV, HCV and HIV and pre-study HBV vaccination status was collected from these individuals. Results The pre-study testing rate among participating hospital staff for HBV was 23.6% (56/237), for HCV 16% (38/237), and for HIV 91.6% (217/237). The pre-study HBV vaccination rate was 12.3% (29/237). Analysis of anti-HBc revealed that 73.4% (174/237) of the hospital staff had been infected by HBV. Active HBV infection (HBsAg positivity) was detected in 15 participants. Anti-HCV was found in four of 237 participants, HIV antibodies were detected in four of 200 participants tested. Conclusion HBV and HCV are neglected diseases among HCW in sub-Saharan Africa. The vaccination rate against HBV was very low at 12.3%, and therefore anti-HBc testing should be mandatory to identify HCW requiring HBV vaccination. Testing for HBV and routine HBV vaccination for HBV-negative HCW should be strongly enforced in Cameroon.


  • Open Access

    Pneumocystis species in Brown Leghorn laying hens—A hint for an extra-mammalian reservoir

    by D. Riebold, E. Mohr, M. Sombetzki, C. Fritzsche, M. Loebermann, E. C. Reisinger


  • High prevalence ofPneumocystis jiroveciicolonization among patients with autoimmune inflammatory diseases and corticosteroid therapy

    by C Fritzsche, D Riebold, Ak Munk-Hartig, S Klammt, G Neeck, Ec Reisinger

    Background: Patients with autoimmune inflammatory diseases (AID) account for 13–36% of Pneumocystis pneumonia (PCP) cases in human immunodeficiency virus (HIV)-negative patients. Up to 88% of PCP cases in HIV-negative patients are associated with prior steroid treatment. Pulmonary colonization with Pneumocystis in HIV-negative patients is associated with corticosteroid therapy in up to 75% of cases. The aim of this study was to detect the prevalence and risk factors of pulmonary colonization with Pneumocystis jirovecii in patients with AID receiving corticosteroid therapy in comparison with healthy control persons. Methods: We investigated induced sputa of 102 patients with AID on current corticosteroid treatment and of 117 healthy controls for the presence of P. jirovecii using polymerase chain reaction (PCR). Results: Twenty-nine patients (28.5%) with AID were colonized with P. jirovecii compared to three healthy controls (2.6%) [p < 0.001, odds ratio (OR) 15.10, 95% confidence interval (CI) 4.43–51.38]. In patients with AID, age over 60 years was significantly associated with colonization (p = 0.015, OR 3.19, 95% CI 1.27–7.94). Multivariate analysis showed age to be independently associated with the colonization of P. jirovecii (95% CI 1.002–1.092). Neither duration nor dose of corticosteroid therapy nor immunosuppressive co-medication had a significant influence on P. jirovecii colonization. Conclusion: Patients with AID, especially those over 60 years of age, display a high prevalence of colonization with P. jirovecii. Clinicians should be aware of this and ensure that they consider the possibility of PCP when pulmonary symptoms arise in these patients.